A REAL-WORLD ANALYSIS OF TREATMENT PATTERNS FOR FIRST-LINE IMMUNOTHERAPIES AMONG DANISH PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND PD-L1 EXPRESSION $50%

被引：0
|
作者：
Clugston, D. M. [1 ]
Beck, C. [2 ]
Bjerregaard, B. K. [3 ]
Kristensen, E. S. [4 ]
机构：
[1] Roche Pharmaceut AS, Copenhagen, Denmark
[2] Roche Pharmaceut AS, Copenhagen 84, Denmark
[3] IQVIA Denmark, Copenhagen, Denmark
[4] IQVIA, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD53
引用
收藏
页码：S514 / S514
页数：1
相关论文
共 50 条
  • [21] First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
    Benetti, B.
    Ferro, A.
    Girardi, F.
    Calvetti, L.
    Pavan, A.
    Mulargiu, C.
    Simionato, F.
    Pretelli, G.
    Lorenzi, M.
    Resi, M. V.
    Marinato, G.
    Dal Maso, A.
    Frega, S.
    Pasello, G.
    Aprile, G.
    Morandi, P.
    Guarneri, V.
    Bonanno, L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S341 - S341
  • [22] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated
    Wang, Q.
    Xu, A.
    Ma, C.
    Wang, T.
    Liu, P.
    Duan, Y.
    Kong, T.
    Chen, G.
    Jia, X.
    Shang, K.
    Yang, G.
    Zhang, G.
    Yu, F.
    Wang, H.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34
  • [23] Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
    E. Pons-Tostivint
    P. Hulo
    V. Guardiolle
    L. Bodot
    A. Rabeau
    M. Porte
    S. Hiret
    P. Demontrond
    H. Curcio
    A. Boudoussier
    R. Veillon
    M. Mayenga
    C. Dumenil
    T. Chatellier
    P. A. Gourraud
    J. Mazieres
    J. Bennouna
    Cancer Immunology, Immunotherapy, 2023, 72 : 1891 - 1892
  • [24] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
    Amrane, Karim
    Geier, Margaux
    Corre, Romain
    Lena, Herve
    Leveiller, Guillaume
    Gadby, Florence
    Lamy, Regine
    Bizec, Jean-Louis
    Goarant, Eric
    Robinet, Gilles
    Gouva, Sylvie
    Quere, Gilles
    Abgral, Ronan
    Schick, Ulrike
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
  • [25] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
    He, Mingfeng
    Zheng, Taihao
    Zhang, Xiaoyue
    Peng, Yuan
    Jiang, Xuan
    Huang, Yusheng
    Tan, Benxu
    Yang, Zhenzhou
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1345 - 1355
  • [26] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
    Mingfeng He
    Taihao Zheng
    Xiaoyue Zhang
    Yuan Peng
    Xuan Jiang
    Yusheng Huang
    Benxu Tan
    Zhenzhou Yang
    Cancer Immunology, Immunotherapy, 2022, 71 : 1345 - 1355
  • [27] PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea
    Sun, Jong-Mu
    Zhou, Wei
    Choi, Yoon-La
    Choi, So-Jung
    Kim, Se Eun
    Wang, Zhen
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Weiner, Russell
    Park, Minjin
    Kim, Hong Kwan
    Choi, Yong Soo
    Shim, Young Mog
    Kim, Jhingook
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.
    Majem, Margarita
    Cobo, Manuel
    Isla, Dolores
    Marquez-Medina, Diego
    Rodriguez-Abreu, Delvys
    Casal Rubio, Joaquin
    Moran Bueno, Teresa
    Bernabe Caro, Reyes
    Perez Parente, Diego
    Ruiz Gracia, Pedro
    Marina Arroyo, Marta
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Real-world evaluation of the effectiveness and predictive factors of anti-PD-1/PD-L1 inhibitors as the first-line therapy for metastatic non-small cell lung cancer
    Chen, Jing
    Yang, Dingyi
    Lei, Qianqian
    Long, Yanyan
    ASIAN JOURNAL OF SURGERY, 2023, 46 (09) : 4103 - 4104
  • [30] Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
    Zhang, Xinke
    DeClue, Richard W.
    Herms, Lisa
    Yang, Mo
    Pawar, Vivek
    Masters, Elizabeth T.
    Ruisi, Mary
    Chin, Kevin
    Velcheti, Vamsidhar
    IMMUNOTHERAPY, 2021, 13 (18) : 1521 - 1533
12345